Sandoz AG

Long-awaited competition to Amgen’s denosumab-based Prolia and Xgeva brands has finally materialized in the US, with Sandoz delivering on its promise to launch the first rivals to the top-selling trea

The latest meeting of the European Medicines Agency’s Committee for Medicinal Products for Human Use resulted in a raft of positive opinions for the off-patent industry. After eight denosumab nods in

After being refused an initial injunction as part of ongoing litigation over a private-label ustekinumab biosimilar being marketed in the US by Sandoz and Samsung Bioepis through a pharmacy benefit ma

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Rznomics To Partner With Lilly On